Palvella Therapeutics Inc (PVLA) USD0.001
Sell:$10.09Buy:$40.33
$0.08
(0.31%)
- This stock can be held in a
Stocks and Shares ISA$0.08
(0.31%)$0.08
(0.31%)Company Information
About this company
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Key people
Key facts
- EPICPVLA
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS6979471090
- Market cap$292.66m
- Employees14
- Shares in issue11.02m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.